vs
STANDARD BIOTOOLS INC.（LAB）与Rhinebeck Bancorp, Inc.（RBKB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Rhinebeck Bancorp, Inc.的1.4倍（$19.6M vs $13.5M），Rhinebeck Bancorp, Inc.净利率更高（17.3% vs -177.4%，领先194.7%），Rhinebeck Bancorp, Inc.同比增速更快（1701.1% vs -11.5%），Rhinebeck Bancorp, Inc.自由现金流更多（$10.9M vs $-23.1M），过去两年Rhinebeck Bancorp, Inc.的营收复合增速更高（14.0% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Rhinebeck Bancorp, Inc.是总部位于美国纽约的区域性银行控股企业，旗下运营莱茵贝克银行，主要面向纽约哈德逊谷地区的个人消费者与中小企业提供储蓄、贷款、抵押贷款、财富管理等零售及商业金融服务。
LAB vs RBKB — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $13.5M |
| 净利润 | $-34.7M | $2.3M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | 21.7% |
| 净利率 | -177.4% | 17.3% |
| 营收同比 | -11.5% | 1701.1% |
| 净利润同比 | -28.8% | 188.0% |
| 每股收益（稀释后） | $-0.09 | $0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $13.5M | ||
| Q3 25 | $19.6M | $14.0M | ||
| Q2 25 | $21.8M | $13.1M | ||
| Q1 25 | $40.8M | $12.8M | ||
| Q4 24 | — | $750.0K | ||
| Q3 24 | $22.1M | $773.0K | ||
| Q2 24 | $22.5M | $10.7M | ||
| Q1 24 | $45.5M | $10.4M |
| Q4 25 | — | $2.3M | ||
| Q3 25 | $-34.7M | $2.7M | ||
| Q2 25 | $-33.5M | $2.7M | ||
| Q1 25 | $-26.0M | $2.3M | ||
| Q4 24 | — | $-2.7M | ||
| Q3 24 | $-26.9M | $-8.1M | ||
| Q2 24 | $-45.7M | $975.0K | ||
| Q1 24 | $-32.2M | $1.1M |
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
| Q4 25 | — | 21.7% | ||
| Q3 25 | -168.5% | 23.9% | ||
| Q2 25 | -118.1% | 26.6% | ||
| Q1 25 | -80.8% | 22.9% | ||
| Q4 24 | — | -444.9% | ||
| Q3 24 | -120.9% | -1332.3% | ||
| Q2 24 | -134.5% | 11.8% | ||
| Q1 24 | -132.2% | 13.9% |
| Q4 25 | — | 17.3% | ||
| Q3 25 | -177.4% | 19.3% | ||
| Q2 25 | -153.7% | 20.8% | ||
| Q1 25 | -63.8% | 17.9% | ||
| Q4 24 | — | -353.9% | ||
| Q3 24 | -122.0% | -1042.9% | ||
| Q2 24 | -203.3% | 9.2% | ||
| Q1 24 | -70.6% | 10.8% |
| Q4 25 | — | $0.21 | ||
| Q3 25 | $-0.09 | $0.25 | ||
| Q2 25 | $-0.09 | $0.25 | ||
| Q1 25 | $-0.07 | $0.21 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | $-0.07 | $-0.75 | ||
| Q2 24 | $-0.12 | $0.09 | ||
| Q1 24 | $-0.27 | $0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $136.9M |
| 总资产 | $539.6M | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | — | ||
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $210.6M | — | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
| Q4 25 | — | $136.9M | ||
| Q3 25 | $399.7M | $133.0M | ||
| Q2 25 | $424.5M | $129.0M | ||
| Q1 25 | $454.6M | $126.0M | ||
| Q4 24 | — | $121.8M | ||
| Q3 24 | $489.3M | $122.7M | ||
| Q2 24 | $510.3M | $116.2M | ||
| Q1 24 | $577.3M | $114.3M |
| Q4 25 | — | $1.3B | ||
| Q3 25 | $539.6M | $1.3B | ||
| Q2 25 | $557.0M | $1.3B | ||
| Q1 25 | $579.6M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | $681.5M | $1.3B | ||
| Q2 24 | $708.7M | $1.3B | ||
| Q1 24 | $777.7M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $11.7M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $10.9M |
| 自由现金流率自由现金流/营收 | -118.1% | 80.6% |
| 资本支出强度资本支出/营收 | 4.5% | 6.3% |
| 现金转化率经营现金流/净利润 | — | 5.03× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $19.4M |
8季度趋势，按日历期对齐
| Q4 25 | — | $11.7M | ||
| Q3 25 | $-22.2M | $2.2M | ||
| Q2 25 | $-20.7M | $2.4M | ||
| Q1 25 | $-30.3M | $4.3M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $-27.9M | $-3.6M | ||
| Q2 24 | $-39.0M | $12.0M | ||
| Q1 24 | $-62.5M | $-3.5M |
| Q4 25 | — | $10.9M | ||
| Q3 25 | $-23.1M | $2.0M | ||
| Q2 25 | $-22.6M | $2.2M | ||
| Q1 25 | $-35.3M | $4.2M | ||
| Q4 24 | — | $7.7M | ||
| Q3 24 | $-30.1M | $-3.6M | ||
| Q2 24 | $-41.0M | $11.8M | ||
| Q1 24 | $-63.3M | $-3.7M |
| Q4 25 | — | 80.6% | ||
| Q3 25 | -118.1% | 14.5% | ||
| Q2 25 | -103.6% | 17.2% | ||
| Q1 25 | -86.6% | 32.8% | ||
| Q4 24 | — | 1023.9% | ||
| Q3 24 | -136.4% | -469.0% | ||
| Q2 24 | -182.2% | 111.1% | ||
| Q1 24 | -138.9% | -36.0% |
| Q4 25 | — | 6.3% | ||
| Q3 25 | 4.5% | 1.4% | ||
| Q2 25 | 8.7% | 1.4% | ||
| Q1 25 | 12.4% | 0.9% | ||
| Q4 24 | — | 105.5% | ||
| Q3 24 | 10.2% | 6.3% | ||
| Q2 24 | 8.6% | 1.2% | ||
| Q1 24 | 1.7% | 2.3% |
| Q4 25 | — | 5.03× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.89× | ||
| Q1 25 | — | 1.89× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.27× | ||
| Q1 24 | — | -3.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
RBKB
暂无分部数据
